Form 8-K

8-K — Rein Therapeutics, Inc.

Accession: 0001193125-26-383726

Filed: 2026-09-04

Period: 2026-09-04

CIK: 0001420565

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — d111215d8k.htm (Primary)

EX-99.1 (d111215dex991.htm)

GRAPHIC (g111215ex99_1p10g1.jpg)

GRAPHIC (g111215ex99_1p11g1.jpg)

GRAPHIC (g111215ex99_1p12g1.jpg)

GRAPHIC (g111215ex99_1p13g1.jpg)

GRAPHIC (g111215ex99_1p14g1.jpg)

GRAPHIC (g111215ex99_1p15g1.jpg)

GRAPHIC (g111215ex99_1p16g1.jpg)

GRAPHIC (g111215ex99_1p17g1.jpg)

GRAPHIC (g111215ex99_1p18g1.jpg)

GRAPHIC (g111215ex99_1p19g1.jpg)

GRAPHIC (g111215ex99_1p1g1.jpg)

GRAPHIC (g111215ex99_1p20g1.jpg)

GRAPHIC (g111215ex99_1p21g1.jpg)

GRAPHIC (g111215ex99_1p22g1.jpg)

GRAPHIC (g111215ex99_1p23g1.jpg)

GRAPHIC (g111215ex99_1p24g1.jpg)

GRAPHIC (g111215ex99_1p25g1.jpg)

GRAPHIC (g111215ex99_1p26g1.jpg)

GRAPHIC (g111215ex99_1p27g1.jpg)

GRAPHIC (g111215ex99_1p28g1.jpg)

GRAPHIC (g111215ex99_1p29g1.jpg)

GRAPHIC (g111215ex99_1p2g1.jpg)

GRAPHIC (g111215ex99_1p30g1.jpg)

GRAPHIC (g111215ex99_1p31g1.jpg)

GRAPHIC (g111215ex99_1p32g1.jpg)

GRAPHIC (g111215ex99_1p33g1.jpg)

GRAPHIC (g111215ex99_1p34g1.jpg)

GRAPHIC (g111215ex99_1p35g1.jpg)

GRAPHIC (g111215ex99_1p36g1.jpg)

GRAPHIC (g111215ex99_1p37g1.jpg)

GRAPHIC (g111215ex99_1p38g1.jpg)

GRAPHIC (g111215ex99_1p39g1.jpg)

GRAPHIC (g111215ex99_1p3g1.jpg)

GRAPHIC (g111215ex99_1p40g1.jpg)

GRAPHIC (g111215ex99_1p41g1.jpg)

GRAPHIC (g111215ex99_1p42g1.jpg)

GRAPHIC (g111215ex99_1p43g1.jpg)

GRAPHIC (g111215ex99_1p44g1.jpg)

GRAPHIC (g111215ex99_1p45g1.jpg)

GRAPHIC (g111215ex99_1p46g1.jpg)

GRAPHIC (g111215ex99_1p47g1.jpg)

GRAPHIC (g111215ex99_1p48g1.jpg)

GRAPHIC (g111215ex99_1p49g1.jpg)

GRAPHIC (g111215ex99_1p4g1.jpg)

GRAPHIC (g111215ex99_1p50g1.jpg)

GRAPHIC (g111215ex99_1p51g1.jpg)

GRAPHIC (g111215ex99_1p52g1.jpg)

GRAPHIC (g111215ex99_1p53g1.jpg)

GRAPHIC (g111215ex99_1p54g1.jpg)

GRAPHIC (g111215ex99_1p55g1.jpg)

GRAPHIC (g111215ex99_1p5g1.jpg)

GRAPHIC (g111215ex99_1p6g1.jpg)

GRAPHIC (g111215ex99_1p7g1.jpg)

GRAPHIC (g111215ex99_1p8g1.jpg)

GRAPHIC (g111215ex99_1p9g1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d111215d8k.htm · Sequence: 1

8-K

NASDAQ false 0001420565 0001420565 2026-09-04 2026-09-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 4, 2026

REIN THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

001-38130

13-4196017

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

12407 N. Mopac Expy., Suite 250, #390

Austin, Texas 78758

(Address of principal executive offices)

(737) 802-1989

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common stock: Par value $.001

RNTX

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

On September 4, 2026, Rein Therapeutics, Inc. (“Company”) published a presentation concerning its LTI-03 product candidate on its website at https://ir.reintx.com/events-presentations. A copy of the presentation is attached as Exhibit 99.1 hereto.

The information in this Item 7.01, including the presentation attached as Exhibit 99.1, are furnished pursuant to Item 7.01 but shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall either be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

Method Filing

The following exhibit is furnished with this report:

Exhibit 99.1

The Company’s presentation materials

Filed Electronically herewith

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REIN THERAPEUTICS, INC.

Dated: September 4, 2026

/s/ Brian Windsor

Brian Windsor, Ph.D.,

President and Chief Executive Officer

EX-99.1

Filename: d111215dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1 Harnessing fibrosis, unleashing life Science Deck|

Forward Looking Statements This presentation and various remarks we make

during this presentation contain forward-looking statements of Rein Therapeutics, Inc. (“Rein”, the “Company”, “we”, “our” or “us”) within the meaning of the Private Securities Litigation

Reform Act of 1995, including statements with respect to: the expected benefits of using CSDs for fibrotic indications and our plans to develop and commercialize LTI-03, including the potential benefits thereof. We use words such as

“anticipate,” ”believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “predict,” “project,” “target,”

“potential,” “would,” “can,” “could,” “should,” “continue,” and other words and terms of similar meaning to help identify forward-looking statements, although not all

forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including (i) the risk that the Company may not be

able to successfully continue its Phase 2 clinical trials of LTI-03; (ii) the risk that the Company may not report data derived from its Phase 2 trial in the second half of 2026 or, if it does, the risk that the data may not support or validate our

expectations concerning the potential benefits of LTI-03; (iii) success in early phases of pre-clinical and clinical trials do not ensure later clinical trials will be successful; (iv) the risk that the Company’s present cash and cash

equivalents may not be sufficient to fund the Company’s operations into the first quarter of 2028 and (v) the risks and uncertainties discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the

year ended December 31, 2025 filed with the Securities and Exchange Commission (the “SEC”) on March 2026 and in the subsequent filings that the Company files with the SEC. These forward-looking statements should not be relied upon as

representing the Company's view as of any date subsequent to the date of this presentation, and we expressly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except

Outline • Our story • Introducing LTI-03 – a novel

treatment for IPF • Rationale for use of caveolin scaffolding domain peptides (CSDs) for fibrotic indications • Background – CAV1 biology and fibrosis • Lead selection and target validation • LTI-03 formulation •

LTI-03 pharmacokinetics • Translating efficacious dosing of LTI-03 • Evidence of alveolar restoration by LTI-03 • Evidence of anti-fibrotic effects of LTI-03 in preclinical fibrosis models • Evidence of LTI-03 biomarker

Therapeutics 4

Pioneering First-in-Class Therapies for Pulmonary & Fibrosis

Indications • Clinical-stage biotech company pioneering first-in-class multi-pathway therapies in orphan pulmonary and fibrosis indications • LTI-03 has demonstrated antifibrotic and regenerative properties o Unique dual mechanism

promoting alveolar epithelial cell survival & inhibiting profibrotic signaling o No treatment-related SAEs and no gastrointestinal tolerability signal over 14 days of inhaled dosing (n=24). Local lung delivery with minimal systemic exposure.

Led by Experienced Biotech and Pulmonary Team Key Management and Board

of Directors Brian Windsor, Ph.D. Joe von Rickenbach TFF, Enavail, Emergent Chief Executive Officer Chairman Paraxel and Director Myokardia, ChemoCentryx Cory H. Hogaboam, Ph.D. Bill Fairey Cedars Sinai Chief Scientific Officer Director Actelion

Alan Musso Tim Cunningham Danforth Advisors Reviral, Peloton, Targacept Director Chief Financial Officer Kristie Lauterbach Reinhard Ambros, Ph.D. Funded by Novartis Takeda VP Quality Director Copyright © 2026 Rein Therapeutics 6

Multiple Orphan Disease Programs Ready for Phase 2 Clinical Trials

Upcoming Milestones Preclinical Phase 1 Phase 2 Phase 3 LTI-03 Idiopathic Pulmonary Fibrosis NOW ENROLLING LTI-01 Loculated Pleural Effusion Ready for Phase 2b initiation Malignant Pleural Effusion LTI-05 Cystic Fibrosis Other Programs Multiple

Therapies for Underserved Fibrosis and Pulmonary Conditions •

Phase 1b clinical trial met primary endpoint: High dose LTI-03 (10mg) and low dose LTI-03 (5mg) was well-tolerated; no treatment-related SAEs. Advancing LTI-03 into Phase • Exploratory biomarkers previously associated in the literature with

lung Idiopathic Pulmonary 2 function decline were directionally consistent with preclinical findings; 5 Fibrosis biomarkers reached nominal significance at the higher dose; 2 in the lower dose • Potentially fatal disease with no approved drugs

LTI-03: A Novel Treatment with Potential to Reverse the Course of IPF

Idiopathic Pulmonary Fibrosis – a Deadly Diagnosis •

Idiopathic Pulmonary Fibrosis, or IPF, is a fatal age-related disease characterized by 1 progressive scarring in the lungs • IPF is part of a larger group of diseases known as Interstitial Lung Diseases, or ILDs, which are diseases

characterized by lung inflammation and/or scarring. There are more than 200 types of Pulmonary Fibrosis 2 conditions within ILDs • Estimated US prevalence is 14 to 43 per 100,000; approximately 40,000 to 110,000 3 adults live with IPF. •

More than 250,000 Americans live with some 2 form of pulmonary fibrosis. • Median survival from the time of diagnosis is 4 3-5 years 1 Mora, A., Rojas, M., Pardo, A. et al. Emerging therapies for idiopathic pulmonary fibrosis, a progressive

age-related disease. Nat Rev Drug Discov 16, 755–772 (2017). 2 https://www.pulmonaryfibrosis.org/understanding-pff/about-pulmonary-fibrosis/what-is-pulmonary-fibrosis 3 Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and

prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810–816. doi:10.1164/rccm.200602-163OC 4 Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J

Sizable Global Opportunity with Potential Upside • Three drugs

approved for IPF as of September 2026 (nintedanib, pirfenidone, nerandomilast) ®️ • Ofev , the global leader, did more than $4B in sales. • Other PF and ILDs represent upside for a successful IPF drug Copyright © 2026

Rein Therapeutics 11

1 Select Competitive Landscape Company Compound Single or Multi-

Mechanism Target Cell Types Clinical Stage pathway Fibroblasts, type 2 Epithelial cells, Caveolin-1 CSD LTI-03 Multi-pathway ENROLLING Aberrant basaloid mimic cells, Macrophages Broad tyrosine Nintedanib Multi-pathway Fibroblasts Approved kinase

inhibitor unknown Fibroblasts Approved Pirfenidone Multi-pathway Aberrant basaloid Nerandomilast Multi-pathway PDE-4B inhibitor Approved cells, Fibroblasts Smoothened Fibroblasts P2 ENV 101 Single antagonist Angiotensin II type Type 2 Epithelium P2b

Rationale for administration of caveolin scaffolding domain peptides

LTI-03: the Critical Portion of the CSD Region of Cav1 Mimics the

Regulatory Activity of Cav1, Affecting a Wide Range of Proteins Involved in Fibrosis • LTI-03 is a seven amino acid peptide comprising a portion of the Cav1 CSD. Substitution/deletion analysis revealed it is the smallest CSD fragment that

retains functionality • This hydrophobic peptide can enter cells, and it may be acting both at the cell membrane and intracellularly • Studies have shown that the LTI-03 peptide can affect phosphorylation of dozens of profibrotic

proteins • LTI-03 is dosed direct to the lungs by dry powder inhaler, and studies have shown that intact peptide can be detected in the lungs 24 hours after administration For a review on CSD/CBD binding domain list, see: Byrne et. al. PLOS

Caveolin-1 Regulates Proteins Involved in Multiple Fibrosis-Related

Pathways in the Lung and Other Organs • Caveolin-1 (Cav1) is a regulator of cellular homeostasis • Cav1 regulates many proteins involved in multiple fibrosis pathways • Cav1 effects its regulation through interacting at the

Caveolin Scaffolding Domain (CSD), a 20 amino acid region that binds proteins and affects trafficking through phosphorylation • Cav1 is lost in a fibrotic state—it is dramatically downregulated both at the transcript and protein level

and thus loses its ability to properly 1 regulate proteins involved in fibrosis • This is not limited to the lung. Cav1 is involved in fibrosis in the heart, skin, kidney, liver, and other organs Adapted from Gvaramia et al, Matrix Biology,

LTI-03’s Dual Mechanism: Broad Antifibrotic Activity Combined

with Epithelial Protection • Approved therapies slow the rate of lung function decline but do not restore lung function • LTI-03 inhibits profibrotic signaling and supports alveolar epithelial cells by replacing caveolin-1 scaffolding

domain activity lost in the IPF lung • LTI-03 works to impact multiple fibrosis pathways • LTI-03 has attenuated fibrosis in preclinical cardiac and dermal models, suggesting potential beyond the lung Copyright © 2026 Rein

Therapeutics 16

Background CAV1 biology and fibrosis CSD peptides guide cells towards

Caveolin-1 mouse knockouts develop thickened lung septa and display

Caveolin-1 is downregulated in IPF Protein expression mRNA levels

SOURCE: Wang XM, Zhang Y, Kim HP, et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary Copyright © 2026 Rein Therapeutics 19 fibrosis. J Exp Med. 2006;203(13):2895-2906. doi:10.1084/jem.20061536.

Endogenous Caveolin-1 is depleted in end stage IPF lungs & during

CAV1 signaling is lost in fibrosis and CSD peptides guide cells of

Lead Selection and Validation Screening for levels of fibrotic

Lead selection In ahuman IPFlung fibroblast screen for pro- fibrotic

proteins, 7-mer (LTI-03) demonstrated maximum efficacy in attenuation of pro- fibrotic factors SOURCE: Marudamuthu AS, Bhandary YP, Fan L, et al. Caveolin-1-derived peptide limits development of pulmonary fibrosis. Sci Transl Med. 2019;11:eaat2848.

Reverse phase protein array (RPPA) indicates that 10uM LTI-03

significantly attenuates a variety of profibrotic signaling pathways in IPF lung fibroblasts RPPA assay, biologically unique IPF lung fibroblasts (N=3) and donor lung fibroblasts (N=3); Shixia Huang; Baylor College of Medicine; Note(s) Data

LTI-03 Attenuates Profibrotic Signaling in Vitro Normal Lung

Fibroblasts IPF Lung Fibroblasts 3000 3000 2500 2500 *** 2000 2000 Normal lung 1500 1500 fibroblast p-EGFR levels 1000 1000 500 500 0 0 Untreated DMSO Control Peptide LTI-03 10uM Untreated DMSO Control Peptide LTI-03 10uM 20000 20000 15000 15000

**** 10000 10000 p-SRC 5000 5000 0 0 Untreated DMSO Control Peptide LTI-03 10uM Untreated DMSO Control Peptide LTI-03 10uM • Factors indicative of aberrant profibrotic signaling were significantly down-regulated exclusively in fibroblasts

derived from IPF patients (n=3), with little to no effects on healthy donor fibroblast lines (n=3); (LTI-03 10uM compared to untreated, DMSO or control peptide) • In IPF, LTI-03 appears to reduce aberrant signaling by supplementing cells with

the Cav1 signaling domain RPPA assay, Shixia Huang; Baylor College of Medicine; Note(s) Data expressed as mean values and SDs. *p < .05; ** p < .01; ***p<.001; ****p < .0001 (DATA UNPUBLISHED) Copyright © 2026 Rein Therapeutics 25

AU AU AU AU

LTI-03 formulation Dry powder: LTI-03 (7-mer) Indication: IPF

LTI-03 is a novel, excipient-free, stable, dry powder peptide - TEM

microscopy indicates micronized LTI-03 is taken up by cells (fibroblasts) post 15min incubation (above) SOURCE: Zhang Y, MacKenzie B, Koleng JJ, Maier E, Warnken ZN, Williams RO III. Development of an Excipient-Free Peptide Dry Powder Copyright

Intact LTI-03 was detected via LC-MS in the canine lung 24hrs post dose

LTI-03 was quantifiable in BALF but below quantification in plasma at

every timepoint in the Ph1b study (NCT05954988) • LTI-03 LLOQ: 1ng/mL • LTI-03 detection rate was not dose-ordered given BALF collection variability Source: Molyneaux, P. L. et al. Inhaled LTI-03 for idiopathic pulmonary fibrosis: a

Translating efficacious dosing of LTI-03 (dry powder / clinical

A 1mg inhaled dose of LTI-03 would give an equivalent lung epithelial

BLM mouse efficacy study doses approximated a 9mg human dose A 0.852

Value Units Parameter RMV(L/min) = 0.608 × BW(Kg) 0.13 mg/L Measured aerosol concentration B DD= C x RMV x D x DF / RM BW V= respiratory minute volume (mouse) 11 min Duration of exposure DD = delivered dose (mg/kg) 0.035 kg Mouse body weight

(BW) A C = concentration (mg/L) Calculated: Alexander, 2008 0.035 LPM RMV = respiratory minute (L/min) B Delivered Dose 1.43 mg/kg D = duration of exposure (min) Deposition Fraction (MPPD3) 2.6% % DF = Deposition Factor (%) Pulmonary Deposited Dose

BW=Body Weight (kg) (PDD) 0.037 mg/kg C HED = HuBW (kg) x muPDD / (%ED x DF) Human BWT muPDD = Pulmonary Deposited Dose 60 kg %ED = Device % emitted dose Mouse PDD x human BWT 2.2 mg 59% % Emitted Dose: Lonza 42.8% % Deposition Factor (MPPD3) Human

Therapeutics 34

Increased LysoTracker signal, consistent with preserved or increased

AEC2 lamellar body content; corroborated by increases in pro-SPC and ABCA3 (PCLS Studies. Effects 48 Hours After Administration) A • Lysotracker dye (Panel A, bright green dots) localizes to AEC2 cells, the progenitor cells of the lung, which

are responsible for making new lung tissue. LTI-03 resulted in an increase in staining, meaning an increase in these critical progenitor cells • Increases in lysotracker staining C B (Panel B) also correlated with increases in surfactant

protein C (pro-SPC) and ABCA3 (the pro- SPC transporter) • Western blots (Panel C) confirm that in the IPF lung SPC levels are diminished, but that LTI-03 causes levels to increase SOURCE: 2019, ERS International Congress. MacKenzie BA et al.

Late Breaking Abstract - Caveolin-1 derived peptide LTI-03 promotes epithelial cell survival and attenuates pulmonary fibrosis. Eur Respir J. 2019;54(Suppl 63):PA1299. doi:10.1183/13993003.congress-2019.PA1299. Copyright © 2026 Rein

Therapeutics 35

LTI-03 increased lysotracker staining in IPF precision cut lung slices

(PCLS) indicating a positive effect on AEC2 cells SOURCE: 2025, ATS International Conference. Jannini-Sa YAP, Coelho AL, MacKenzie B, Hogaboam CM. Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides (CSD) in Three

Dimensional (3D) Alveolospheres From IPF and Normal Donor Lung Samples. Am J Respir Crit Care Med. 2025;211(Suppl 1):A4691. doi:10.1164/ajrccm.2025.211.Abstracts.A4691. Copyright © 2026 Rein Therapeutics 36

LTI-03 treatment increased alveolar organoid area in 4 distinct IPF

patients SOURCE: 2025, ATS International Conference. Jannini-Sa YAP, Coelho AL, MacKenzie B, Hogaboam CM. Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides (CSD) in Three Dimensional (3D) Alveolospheres From IPF and Normal

LTI-03 sustained donor lung organoid growth (n=2 donors) SOURCE:

Adapted from 2025, ATS International Conference. Jannini-Sa YAP, Coelho AL, MacKenzie B, Hogaboam CM. Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides (CSD) in Three Dimensional (3D) Alveolospheres From IPF and Normal

Evidence of anti-fibrotic effects of LTI-03 in preclinical fibrosis

LTI-03 decreased COL1A1 and PDGFRB expression in end-stage IPF PCLS

SOURCE: MacKenzie BA, Mahavadi P, Jannini-Sa YAP, et al. LTI-03 peptide demonstrates anti-fibrotic activity Copyright © 2026 Rein Therapeutics 40 in ex vivo lung slices from patients with IPF. iScience. 2025;28:113437.

doi:10.1016/j.isci.2025.113437.

Antifibrotic Activity: Single dose LTI-03 inhibits multiple profibrotic

proteins similar to Ofev® (Every 12hrs in Precision Cut Lung Slices (PCLS)—Single Patient Sample; CP: control peptide) • As an antifibrotic, LTI-03 inhibits large panels of profibrotic proteins in a manner similar to the standard of

care drug Ofev® (nintedanib) ▪ Darker purple = more inhibition of the protein • The PCLS tissue culture system uses actual biopsied tissue from an IPF lung (removed due to lung transplant), preserving all cell types in the IPF lung

• 10 µM LTI-03 is equivalent to an approximate dose of 1 mg in a dry powder inhaler. Phase 1b trial tested 5mg and 10mg, both of which were safe and well tolerated • TSLP and IL-11 were attenuated by LTI-03 and Nintedanib Day 4

Inhaled LTI-03 attenuated BLM induced fibrosis as well as COL1A1 and

GAL7 in aged, male mice SOURCE: 2022, ATS International Conference. MacKenzie B, Maier E, Creyns B, Coelho AL, Windsor B, Hogaboam CM. Caveolin Scaffolding Domain LTI-03 Modulates Both Inflammatory and Fibrotic Responses in Aged Mice After Bleomycin

Inhaled LTI-03 attenuated IL-11 in BAL of aged, male mice in an acute

lung bleo lung injury model when administered preventatively or prophylactically SOURCE: 2022, ATS International Conference. MacKenzie B, Maier E, Creyns B, Coelho AL, Windsor B, Hogaboam CM. Caveolin Scaffolding Domain LTI-03 Modulates Both

Inflammatory and Fibrotic Responses in Aged Mice After Bleomycin Challenge. Am J Respir Crit Care Med. Copyright © 2026 Rein Therapeutics 43 2022;205(Suppl 1):A2307. doi:10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A2307.

Therapeutic dosing of inhaled LTI-03 (days 14 – 20) ameliorated

fibrosis in the 21-day bleo mouse model of IPF BLM Saline None LTI-03 CP The bleomycin mouse model is the standard preclinical model for assessing anti-fibrotic activity; therapeutic dosing after fibrosis is established is the more stringent test

Copyright © 2026 Rein Therapeutics 44 SOURCE: Marudamuthu AS, Bhandary YP, Fan L, et al. Caveolin-1-derived peptide limits development of pulmonary fibrosis. Sci Transl Med. 2019;11:eaat2848. doi:10.1126/scitranslmed.aat2848. Trichrome staining

(200x) collagen measurements

In both the Adv-TGFP and the BLM mouse models of fibrosis, LTI-03

reduced myeloperoxidase and immune cell recruitment to the lung SOURCE: Marudamuthu AS, Bhandary YP, Fan L, et al. Caveolin-1-derived peptide limits development of pulmonary Copyright © 2026 Rein Therapeutics 45 fibrosis. Sci Transl Med.

2019;11:eaat2848. doi:10.1126/scitranslmed.aat2848.

Evidence of LTI-03 biomarker activity in Ph1b clinical trial

Phase 1b (NCT05954988) Clinical Trial Design—Focus on Safety,

Tolerability, and Biomarkers (Status: Complete) SOURCE: 2026, ERS International Congress, Barcelona. Molyneaux PL et al. Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study. Late-breaking abstract accepted for ERS

Ph1b exploratory biomarkers were pre-specified from nonclinical data

and measured in plasma, peripheral blood mononuclear cells (PBMCs) and deep bronchial brushings (DBBs) LTI-03 preclinical efficacy Caveolin-1 IPF molecular experiments pathogenesis biology Matrix Analytes Method Platelet-rich SP-D MSD-ECL plasma

clinical pAKT / biomarker PBMCs MSD-ECL total AKT candidate TSLP IL-11 DBBs COL1A1 ELISA IPF Surrogate molecular CXCL7 measurement of pathogenesis GAL-7 target engagement Molecular effects signal (CSD regulatory of LTI-03 on attenuation effects)

®️ * Surfactant Protein D (SPD) is an important biomarker

for the approved IPF drug Ofev • SPD is an indicator of epithelial cell health, an important cell type for proper lung function • SPD has been significantly linked to decline in lung function • SPD was reduced by 4% by Ofev over 12

weeks in the INMARK clinical trial • LTI-03 (10mg) decreased plasma SPD by 4.6% over two weeks in the Phase 1b trial; (p=0.111; n=8 vs 5 pooled placebo; exploratory) Nintedanib versus placebo. Fold changes from baseline in SP-D at week 12

corresponded to a 4% decrease and 3% increase in the nintedanib and placebo groups, respectively (ratio 0.94 [95% CI: 0.89, 0.99]; p=0.024). *Jenkins RG, Cottin V, Nishioka Y, et al. Effects of nintedanib on circulating biomarkers of idiopathic

pulmonary fibrosis. ERJ Open Res 2024; 2024;10(6):00558-2023. SOURCE: Molyneaux, P. L. et al. Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study. Nat. Commun. 17, 7620 (2026).

LTI-03 Ph1b exploratory biomarkers assayed in deep bronchial brushings

reached nominal significance (one-tailed Mann-Whitney vs pooled placebo; unadjusted for multiplicity); no significant change in p-AKT/AKT in PBMCs • All exploratory biomarkers have: ✓ Supporting literature suggesting their involvement

in IPF pathogenesis ✓ Are primarily found in important cell types in the IPF lung ✓ Been shown in preclinical studies to be attenuated by LTI-03 • Ph1b data suggests: ✓ LTI-03 biomarker attenuation is consistent with

target engagement ✓ LTI-03 is positively affecting pathogenic factors in the IPF lung SOURCE: 2026, ERS International Congress, Barcelona. Molyneaux PL et al. Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation

2026 Rein Therapeutics 51

Peer reviewed supporting publications 1. Molyneaux PL et al. Inhaled

LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study. Nat Commun. 2026;17:7620. doi:10.1038/s41467-026-75291-3. 2. Fan L, Shetty RS, Dao HM, et al. p53-miR-34a feedback in lung fibroblasts regulates antifibrotic effects of

CSP7, nintedanib, and pirfenidone. Am J Physiol Lung Cell Mol Physiol. 2025;329:L480-L498. doi:10.1152/ajplung.00295.2024. 3. MacKenzie BA, Mahavadi P, Jannini-Sa YAP, et al. LTI-03 peptide demonstrates anti-fibrotic activity in ex vivo lung slices

from patients with IPF. iScience. 2025;28:113437. doi:10.1016/j.isci.2025.113437. 4. Reese CF, Chinnakkannu P, Tourkina E, Hoffman S, Kuppuswamy D. Multiple subregions within the caveolin-1 scaffolding domain inhibit fibrosis, microvascular leakage,

and monocyte migration. PLoS One. 2022;17:e0264413. doi:10.1371/journal.pone.0264413. 5. Kuppuswamy D, Chinnakkannu P, Reese C, Hoffman S. The Caveolin-1 Scaffolding Domain Peptide Reverses Aging-Associated Deleterious Changes in Multiple Organs. J

Pharmacol Exp Ther. 2021;378:1-9. doi:10.1124/jpet.120.000424. 6. Zhang Y, MacKenzie B, Koleng JJ, Maier E, Warnken ZN, Williams RO III. Development of an Excipient-Free Peptide Dry Powder Inhalation for the Treatment of Pulmonary Fibrosis. Mol

Pharm. 2020;17(2):632-644. doi:10.1021/acs.molpharmaceut.9b01085. 7. Marudamuthu AS, Bhandary YP, Fan L, et al. Caveolin-1-derived peptide limits development of pulmonary fibrosis. Sci Transl Med. 2019;11:eaat2848. doi:10.1126/scitranslmed.aat2848.

8. Chinnakkannu P, Reese C, Gaspar JA, et al. Suppression of angiotensin II-induced pathological changes in heart and kidney by the caveolin-1 scaffolding domain peptide. PLoS One. 2018;13(12):e0207844. doi:10.1371/journal.pone.0207844. 9.

Surasarang SH, Florova G, Komissarov AA, Shetty S, Idell S, Williams RO III. Formulation for a novel inhaled peptide therapeutic for idiopathic pulmonary fibrosis. Drug Dev Ind Pharm. 2018;44(2):184-198. doi:10.1080/03639045.2017.1371736. 10. Tepper

JS, Kuehl PJ, Cracknell S, Nikula KJ, Pei L, Blanchard JD. Symposium Summary: Breathe In, Breathe Out, Its Easy: What You Need to Know About Developing Inhaled Drugs . Int J Toxicol. 2016;35(4):376-392. doi:10.1177/1091581815624080. 11. Tourkina E,

Richard M, Gooz P, et al. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol. 2008;294(5):L843-L861. doi:10.1152/ajplung.00295.2007. 12. Wang XM, Zhang Y, Kim HP, et al. Caveolin-1: a

critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med. 2006;203(13):2895-2906. doi:10.1084/jem.20061536. 13. Gvaramia D, Blaauboer ME, Hanemaaijer R, Everts V. Role of caveolin-1 in fibrotic diseases. Matrix Biol.

Peer reviewed supporting abstracts 1. 2026, ERS International Congress,

Barcelona. Molyneaux PL et al. Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study. Late-breaking abstract accepted for ERS International Congress 2026. Public ERJ abstract number and DOI not yet indexed as of

September 2, 2026. 2. 2025, ATS International Conference. Jannini-Sa YAP, Coelho AL, MacKenzie B, Hogaboam CM. Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides (CSD) in Three Dimensional (3D) Alveolospheres From IPF and

Normal Donor Lung Samples. Am J Respir Crit Care Med. 2025;211(Suppl 1):A4691. doi:10.1164/ajrccm.2025.211.Abstracts.A4691. 3. 2025, ATS International Conference. Mahavadi P et al. Pre-clinical Proof-of-Concept of Anti-fibrotic Activity of

Caveolin-1 Scaffolding Domain Peptide LTI-03 in Ex Vivo Precision Cut Lung Slices From Patients With Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2025;211(Suppl 1):A4651. doi:10.1164/ajrccm.2025.211.Abstracts.A4651. 4. 2024, 22nd

International Colloquium on Lung and Airway Fibrosis (ICLAF). Inhalation of LTI-03 Modulates Multiple Targets in a Phase 1B Placebo Controlled Clinical Trial for IPF. Abstract 0183. 5. 2024, 22nd International Colloquium on Lung and Airway Fibrosis

(ICLAF). Anti-Fibrotic Activity of Caveolin-1 scaffolding domain Peptide LTI-03 in Ex Vivo Precision Cut Lung Slices from Patients with Idiopathic Pulmonary Fibrosis. Abstract 0186. 6. 2022, ATS International Conference. Creyns B, MacKenzie B,

Coelho AL, Windsor JB, Hogaboam CM. Caveolin Scaffolding Domain (CSD) Peptide LTI-2355 Modulates Phagocytic and Synthetic Activity of Idiopathic Pulmonary Fibrosis (IPF) Myeloid Cells. Am J Respir Crit Care Med. 2022;205(Suppl 1):A5341.

doi:10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5341. 7. 2022, ATS International Conference. MacKenzie B, Maier E, Creyns B, Coelho AL, Windsor B, Hogaboam CM. Caveolin Scaffolding Domain LTI-03 Modulates Both Inflammatory and Fibrotic

Responses in Aged Mice After Bleomycin Challenge. Am J Respir Crit Care Med. 2022;205(Suppl 1):A2307. doi:10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A2307. 8. 2020, ATS International Conference. Shetty S et al. Caveolin-1-Derived Peptide

Limits Development of Pulmonary Fibrosis. Am J Respir Crit Care Med. 2020;201(Suppl 1):A7881. doi:10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A7881. 9. 2019, ERS International Congress. MacKenzie BA et al. Late Breaking Abstract -

Caveolin-1 derived peptide LTI-03 promotes epithelial cell survival and attenuates pulmonary fibrosis. Eur Respir J. 2019;54(Suppl 63):PA1299. doi:10.1183/13993003.congress-2019.PA1299. 10. 2017, Pulmonary Fibrosis Foundation Summit. Surasarang SH

et al. Resolution of a rodent model of pulmonary fibrosis with a novel peptide delivered by nebulization. Poster presented at the Pulmonary Fibrosis Foundation Summit, 2017. Copyright © 2026 Rein Therapeutics 55

GRAPHIC

Filename: g111215ex99_1p10g1.jpg · Sequence: 6

Binary file (403074 bytes)

Download g111215ex99_1p10g1.jpg

GRAPHIC

Filename: g111215ex99_1p11g1.jpg · Sequence: 7

Binary file (203920 bytes)

Download g111215ex99_1p11g1.jpg

GRAPHIC

Filename: g111215ex99_1p12g1.jpg · Sequence: 8

Binary file (303564 bytes)

Download g111215ex99_1p12g1.jpg

GRAPHIC

Filename: g111215ex99_1p13g1.jpg · Sequence: 9

Binary file (200646 bytes)

Download g111215ex99_1p13g1.jpg

GRAPHIC

Filename: g111215ex99_1p14g1.jpg · Sequence: 10

Binary file (355835 bytes)

Download g111215ex99_1p14g1.jpg

GRAPHIC

Filename: g111215ex99_1p15g1.jpg · Sequence: 11

Binary file (340111 bytes)

Download g111215ex99_1p15g1.jpg

GRAPHIC

Filename: g111215ex99_1p16g1.jpg · Sequence: 12

Binary file (338367 bytes)

Download g111215ex99_1p16g1.jpg

GRAPHIC

Filename: g111215ex99_1p17g1.jpg · Sequence: 13

Binary file (110673 bytes)

Download g111215ex99_1p17g1.jpg

GRAPHIC

Filename: g111215ex99_1p18g1.jpg · Sequence: 14

Binary file (336291 bytes)

Download g111215ex99_1p18g1.jpg

GRAPHIC

Filename: g111215ex99_1p19g1.jpg · Sequence: 15

Binary file (293819 bytes)

Download g111215ex99_1p19g1.jpg

GRAPHIC

Filename: g111215ex99_1p1g1.jpg · Sequence: 16

Binary file (382566 bytes)

Download g111215ex99_1p1g1.jpg

GRAPHIC

Filename: g111215ex99_1p20g1.jpg · Sequence: 17

Binary file (352691 bytes)

Download g111215ex99_1p20g1.jpg

GRAPHIC

Filename: g111215ex99_1p21g1.jpg · Sequence: 18

Binary file (322881 bytes)

Download g111215ex99_1p21g1.jpg

GRAPHIC

Filename: g111215ex99_1p22g1.jpg · Sequence: 19

Binary file (139628 bytes)

Download g111215ex99_1p22g1.jpg

GRAPHIC

Filename: g111215ex99_1p23g1.jpg · Sequence: 20

Binary file (431908 bytes)

Download g111215ex99_1p23g1.jpg

GRAPHIC

Filename: g111215ex99_1p24g1.jpg · Sequence: 21

Binary file (354850 bytes)

Download g111215ex99_1p24g1.jpg

GRAPHIC

Filename: g111215ex99_1p25g1.jpg · Sequence: 22

Binary file (264835 bytes)

Download g111215ex99_1p25g1.jpg

GRAPHIC

Filename: g111215ex99_1p26g1.jpg · Sequence: 23

Binary file (121456 bytes)

Download g111215ex99_1p26g1.jpg

GRAPHIC

Filename: g111215ex99_1p27g1.jpg · Sequence: 24

Binary file (445072 bytes)

Download g111215ex99_1p27g1.jpg

GRAPHIC

Filename: g111215ex99_1p28g1.jpg · Sequence: 25

Binary file (107987 bytes)

Download g111215ex99_1p28g1.jpg

GRAPHIC

Filename: g111215ex99_1p29g1.jpg · Sequence: 26

Binary file (121755 bytes)

Download g111215ex99_1p29g1.jpg

GRAPHIC

Filename: g111215ex99_1p2g1.jpg · Sequence: 27

Binary file (665358 bytes)

Download g111215ex99_1p2g1.jpg

GRAPHIC

Filename: g111215ex99_1p30g1.jpg · Sequence: 28

Binary file (325206 bytes)

Download g111215ex99_1p30g1.jpg

GRAPHIC

Filename: g111215ex99_1p31g1.jpg · Sequence: 29

Binary file (137076 bytes)

Download g111215ex99_1p31g1.jpg

GRAPHIC

Filename: g111215ex99_1p32g1.jpg · Sequence: 30

Binary file (329917 bytes)

Download g111215ex99_1p32g1.jpg

GRAPHIC

Filename: g111215ex99_1p33g1.jpg · Sequence: 31

Binary file (345037 bytes)

Download g111215ex99_1p33g1.jpg

GRAPHIC

Filename: g111215ex99_1p34g1.jpg · Sequence: 32

Binary file (86774 bytes)

Download g111215ex99_1p34g1.jpg

GRAPHIC

Filename: g111215ex99_1p35g1.jpg · Sequence: 33

Binary file (443698 bytes)

Download g111215ex99_1p35g1.jpg

GRAPHIC

Filename: g111215ex99_1p36g1.jpg · Sequence: 34

Binary file (288985 bytes)

Download g111215ex99_1p36g1.jpg

GRAPHIC

Filename: g111215ex99_1p37g1.jpg · Sequence: 35

Binary file (241395 bytes)

Download g111215ex99_1p37g1.jpg

GRAPHIC

Filename: g111215ex99_1p38g1.jpg · Sequence: 36

Binary file (245765 bytes)

Download g111215ex99_1p38g1.jpg

GRAPHIC

Filename: g111215ex99_1p39g1.jpg · Sequence: 37

Binary file (130681 bytes)

Download g111215ex99_1p39g1.jpg

GRAPHIC

Filename: g111215ex99_1p3g1.jpg · Sequence: 38

Binary file (210362 bytes)

Download g111215ex99_1p3g1.jpg

GRAPHIC

Filename: g111215ex99_1p40g1.jpg · Sequence: 39

Binary file (416245 bytes)

Download g111215ex99_1p40g1.jpg

GRAPHIC

Filename: g111215ex99_1p41g1.jpg · Sequence: 40

Binary file (322926 bytes)

Download g111215ex99_1p41g1.jpg

GRAPHIC

Filename: g111215ex99_1p42g1.jpg · Sequence: 41

Binary file (358518 bytes)

Download g111215ex99_1p42g1.jpg

GRAPHIC

Filename: g111215ex99_1p43g1.jpg · Sequence: 42

Binary file (326300 bytes)

Download g111215ex99_1p43g1.jpg

GRAPHIC

Filename: g111215ex99_1p44g1.jpg · Sequence: 43

Binary file (490787 bytes)

Download g111215ex99_1p44g1.jpg

GRAPHIC

Filename: g111215ex99_1p45g1.jpg · Sequence: 44

Binary file (312935 bytes)

Download g111215ex99_1p45g1.jpg

GRAPHIC

Filename: g111215ex99_1p46g1.jpg · Sequence: 45

Binary file (137684 bytes)

Download g111215ex99_1p46g1.jpg

GRAPHIC

Filename: g111215ex99_1p47g1.jpg · Sequence: 46

Binary file (419321 bytes)

Download g111215ex99_1p47g1.jpg

GRAPHIC

Filename: g111215ex99_1p48g1.jpg · Sequence: 47

Binary file (263773 bytes)

Download g111215ex99_1p48g1.jpg

GRAPHIC

Filename: g111215ex99_1p49g1.jpg · Sequence: 48

Binary file (332192 bytes)

Download g111215ex99_1p49g1.jpg

GRAPHIC

Filename: g111215ex99_1p4g1.jpg · Sequence: 49

Binary file (80396 bytes)

Download g111215ex99_1p4g1.jpg

GRAPHIC

Filename: g111215ex99_1p50g1.jpg · Sequence: 50

Binary file (452501 bytes)

Download g111215ex99_1p50g1.jpg

GRAPHIC

Filename: g111215ex99_1p51g1.jpg · Sequence: 51

Binary file (264726 bytes)

Download g111215ex99_1p51g1.jpg

GRAPHIC

Filename: g111215ex99_1p52g1.jpg · Sequence: 52

Binary file (81035 bytes)

Download g111215ex99_1p52g1.jpg

GRAPHIC

Filename: g111215ex99_1p53g1.jpg · Sequence: 53

Binary file (49905 bytes)

Download g111215ex99_1p53g1.jpg

GRAPHIC

Filename: g111215ex99_1p54g1.jpg · Sequence: 54

Binary file (499721 bytes)

Download g111215ex99_1p54g1.jpg

GRAPHIC

Filename: g111215ex99_1p55g1.jpg · Sequence: 55

Binary file (449179 bytes)

Download g111215ex99_1p55g1.jpg

GRAPHIC

Filename: g111215ex99_1p5g1.jpg · Sequence: 56

Binary file (238004 bytes)

Download g111215ex99_1p5g1.jpg

GRAPHIC

Filename: g111215ex99_1p6g1.jpg · Sequence: 57

Binary file (249552 bytes)

Download g111215ex99_1p6g1.jpg

GRAPHIC

Filename: g111215ex99_1p7g1.jpg · Sequence: 58

Binary file (230779 bytes)

Download g111215ex99_1p7g1.jpg

GRAPHIC

Filename: g111215ex99_1p8g1.jpg · Sequence: 59

Binary file (275289 bytes)

Download g111215ex99_1p8g1.jpg

GRAPHIC

Filename: g111215ex99_1p9g1.jpg · Sequence: 60

Binary file (127026 bytes)

Download g111215ex99_1p9g1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 62

v3.26.1

Document and Entity Information

Sep. 04, 2026

Cover [Abstract]

Security Exchange Name

NASDAQ

Amendment Flag

false

Entity Central Index Key

0001420565

Document Type

8-K

Document Period End Date

Sep. 04, 2026

Entity Registrant Name

REIN THERAPEUTICS, INC.

Entity Incorporation State Country Code

Entity File Number

001-38130

Entity Tax Identification Number

13-4196017

Entity Address, Address Line One

12407 N. Mopac Expy.

Entity Address, Address Line Two

Suite 250

Entity Address, Address Line Three

#390

Entity Address, City or Town

Austin

Entity Address, State or Province

Entity Address, Postal Zip Code

78758

City Area Code

(737)

Local Phone Number

802-1989

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common stock: Par value $.001

Trading Symbol

RNTX

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration